Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety Study of GMA161 in Patients With Idiopathic Thrombocytopenic Purpura (ITP)

This study has been terminated.
(Study terminated due to low enrollment.)
Sponsor:
Information provided by:
Genzyme, a Sanofi Company
ClinicalTrials.gov Identifier:
NCT00244257
First received: October 25, 2005
Last updated: July 29, 2009
Last verified: June 2008
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: July 2008
  Estimated Primary Completion Date: No date given